Search results
Added:
3 years ago
Pulmonary hypertension is classified into five groups by the World Health Organization (WHO). Group 1, pulmonary arterial hypertension (PAH), is a progressive disease characterized by an elevation in pulmonary arterial pressure and pulmonary vascular resistance that may progress to right heart dysfunction and failure.1 PAH is defined as a mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest,…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) has an estimated prevalence of 15–25 cases/million population.1 This chronic, progressive disease is defined by a mean pulmonary arterial pressure >25mmHg in conjunction with normal pulmonary capillary wedge pressure <15mmHg.2 The disease is characterized by increased vascular resistance of the pulmonary microvasculature, ultimately resulting in right…
View more
Added:
3 years ago
Pulmonary hypertension (PH) is a hemodynamic condition defined by pulmonary arterial systolic pressure (PASP) above an upper limit of 35mmHg, or by pulmonary arterial mean pressure (PAMP) exceeding 25mmHg at rest.1,2 Pulmonary arterial hypertension (PAH) is present when pre-capillary pulmonary vascular pressure is elevated in the absence of pulmonary capillary wedge pressure >15mmHg, such as…
View more
Added:
3 years ago
Introduction
Pulmonary arterial hypertension (PAH) is a disease affecting the pulmonary vascular endothelium of the small pulmonary vessels that causes progressive elevations in pulmonary vascular resistance, leading to right ventricular failure and death. PAH can result from a number of causes or associated risk factors. A clinical classification (Evian classification) was developed in 1993 and…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a disease affecting the pulmonary vascular endothelium of the small pulmonary vessels that causes progressive elevations in pulmonary vascular resistance, leading to right ventricular failure and death. PAH can result from a number of causes or associated risk factors. A clinical classification (Evian classification) was developed in 1993 and subsequently…
View more
Added:
3 years ago
Pulmonary hypertension (PH) is a hemodynamic condition defined by pulmonary arterial systolic pressure (PASP) above an upper limit of 35mmHg, or by pulmonary arterial mean pressure (PAMP) exceeding 25mmHg at rest. Pulmonary arterial hypertension (PAH) is present when pre-capillary pulmonary vascular pressure is elevated in the absence of pulmonary capillary wedge pressure >15mmHg, such as that…
View more
Added:
3 years ago
Added:
3 years ago
This article will attempt to cover the areas of historic background, current status, newer applications of existing tracers, attenuation correction, metabolic imaging, sympathetic imaging, new stress agents, molecular imaging, and positron emission tomography (PET) without on-site cyclotron. By no means is it meant to be inclusive of all that is currently happening but rather to illustrate some…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition that has traditionally required treatment with continuous intravenous epoprostenol via an indwelling central catheter.1–3 Such therapy improves outcome, but is fraught with side effects, expense, and risk of catheter-related complications. Therapy of PAH has evolved tremendously in recent years, reflecting the…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a progressive increase in pulmonary artery pressure and pulmonary vascular resistance, leading to right ventricular failure and death.1 The recent World Health Organization (WHO) classification designates PAH as Group I and includes idiopathic PAH (IPAH)—formerly known as primary pulmonary hypertension (PPH)…
View more
